tirzepatide cause death linked to lower risk for death, adverse CV and kidney outcomes vs. GLP-1s Effectiveness of tirzepatide in patients

Sources Lilly investor news Eli Lilly FDA drug approval process FDA.gov Related reading Retatrutide Phase 3 Results 2026: TRIUMPH Trial Tracker Living tracker of every retatrutide trial TRIUMPH-1/2/3/4/5, TRIUMPH-Outcomes, TRANSCEND-T2D-1/2, and SYNERGY-OUTCOMES Phase 3 readouts

Retail versus compounded fulfillment A prescription may route to a retail pharmacy for an FDA-approved brand tirzepatide product or to a licensed 503A pharmacy for a compounded preparation, which is not an FDA-approved finished drug product

Results Upregulation of GLP-1R in the TNC after chronic NTG injection To examine whether GLP-1R was expressed in the TNC, we performed immunofluorescence for GLP-1R using a specific antibody, and our images showed that GLP-1R was specifically expressed in the TNC in normal mice (Fig

Amyloid & tau modulation : In mouse models of AD, GLP-1 RAs reduce amyloid oligomer levels and plaque load